Titre : Protéines MutS

Protéines MutS : Questions médicales fréquentes

Termes MeSH sélectionnés :

Immunization Programs
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Protéines MutS : Questions médicales les plus fréquentes", "headline": "Protéines MutS : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Protéines MutS : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-03-25", "dateModified": "2025-03-20", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Protéines MutS" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines de liaison à l'ADN", "url": "https://questionsmedicales.fr/mesh/D004268", "about": { "@type": "MedicalCondition", "name": "Protéines de liaison à l'ADN", "code": { "@type": "MedicalCode", "code": "D004268", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.260" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Protéine MutS de liaison aux mésappariements de l'ADN", "alternateName": "MutS DNA Mismatch-Binding Protein", "url": "https://questionsmedicales.fr/mesh/D051719", "about": { "@type": "MedicalCondition", "name": "Protéine MutS de liaison aux mésappariements de l'ADN", "code": { "@type": "MedicalCode", "code": "D051719", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.260.556.500" } } }, { "@type": "MedicalWebPage", "name": "Protéine-3 homologue de MutS", "alternateName": "MutS Homolog 3 Protein", "url": "https://questionsmedicales.fr/mesh/D000074081", "about": { "@type": "MedicalCondition", "name": "Protéine-3 homologue de MutS", "code": { "@type": "MedicalCode", "code": "D000074081", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.260.556.875" } } } ], "about": { "@type": "MedicalCondition", "name": "Protéines MutS", "alternateName": "MutS Proteins", "code": { "@type": "MedicalCode", "code": "D000074080", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Taiki Futagami", "url": "https://questionsmedicales.fr/author/Taiki%20Futagami", "affiliation": { "@type": "Organization", "name": "United Graduate School of Agricultural Sciences, Kagoshima University, Kagoshima 890-0065, Japan; Graduate School of Agriculture, Forestry and Fisheries, Kagoshima University, Kagoshima 890-0065, Japan; Education and Research Center for Fermentation Studies, Faculty of Agriculture, Kagoshima University, Kagoshima 890-0065, Japan. Electronic address: futagami@agri.kagoshima-u.ac.jp." } }, { "@type": "Person", "name": "Kayu Okutsu", "url": "https://questionsmedicales.fr/author/Kayu%20Okutsu", "affiliation": { "@type": "Organization", "name": "Graduate School of Agriculture, Forestry and Fisheries, Kagoshima University, Kagoshima 890-0065, Japan; Education and Research Center for Fermentation Studies, Faculty of Agriculture, Kagoshima University, Kagoshima 890-0065, Japan." } }, { "@type": "Person", "name": "Yumiko Yoshizaki", "url": "https://questionsmedicales.fr/author/Yumiko%20Yoshizaki", "affiliation": { "@type": "Organization", "name": "United Graduate School of Agricultural Sciences, Kagoshima University, Kagoshima 890-0065, Japan; Graduate School of Agriculture, Forestry and Fisheries, Kagoshima University, Kagoshima 890-0065, Japan; Education and Research Center for Fermentation Studies, Faculty of Agriculture, Kagoshima University, Kagoshima 890-0065, Japan." } }, { "@type": "Person", "name": "Kazunori Takamine", "url": "https://questionsmedicales.fr/author/Kazunori%20Takamine", "affiliation": { "@type": "Organization", "name": "United Graduate School of Agricultural Sciences, Kagoshima University, Kagoshima 890-0065, Japan; Graduate School of Agriculture, Forestry and Fisheries, Kagoshima University, Kagoshima 890-0065, Japan; Education and Research Center for Fermentation Studies, Faculty of Agriculture, Kagoshima University, Kagoshima 890-0065, Japan." } }, { "@type": "Person", "name": "Hisanori Tamaki", "url": "https://questionsmedicales.fr/author/Hisanori%20Tamaki", "affiliation": { "@type": "Organization", "name": "United Graduate School of Agricultural Sciences, Kagoshima University, Kagoshima 890-0065, Japan; Graduate School of Agriculture, Forestry and Fisheries, Kagoshima University, Kagoshima 890-0065, Japan; Education and Research Center for Fermentation Studies, Faculty of Agriculture, Kagoshima University, Kagoshima 890-0065, Japan." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Impact of the national hepatitis B immunization program in China: a modeling study.", "datePublished": "2022-10-11", "url": "https://questionsmedicales.fr/article/36221140", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s40249-022-01032-5" } }, { "@type": "ScholarlyArticle", "name": "Parental knowledge on the respiratory syncytial virus before the nirsevimab immunization program: Attitudes toward immunization in an autonomous community of Spain.", "datePublished": "2024-06-10", "url": "https://questionsmedicales.fr/article/38857859", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/21645515.2024.2357439" } }, { "@type": "ScholarlyArticle", "name": "Cost-benefit analysis of rotavirus vaccine included in the national immunization program in China.", "datePublished": "2022-12-08", "url": "https://questionsmedicales.fr/article/36503856", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.vaccine.2022.11.074" } }, { "@type": "ScholarlyArticle", "name": "Investigation of non-National Immunization Program vaccination intentions in rural areas of China.", "datePublished": "2023-08-04", "url": "https://questionsmedicales.fr/article/37542236", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12889-023-16390-4" } }, { "@type": "ScholarlyArticle", "name": "Vaccination compliance of selected childhood immunization programs and the socio-determinant factors in Nigeria.", "datePublished": "2023-10-31", "url": "https://questionsmedicales.fr/article/37956381", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3855/jidc.17886" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines de liaison à l'ADN", "item": "https://questionsmedicales.fr/mesh/D004268" }, { "@type": "ListItem", "position": 5, "name": "Protéines MutS", "item": "https://questionsmedicales.fr/mesh/D000074080" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Protéines MutS - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Protéines MutS", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-13", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Protéines MutS", "description": "Comment diagnostiquer une déficience en protéines MutS ?\nQuels tests sont utilisés pour évaluer l'activité des protéines MutS ?\nLes biopsies peuvent-elles aider au diagnostic ?\nQuels symptômes peuvent indiquer un problème avec MutS ?\nY a-t-il des marqueurs biologiques associés à MutS ?", "url": "https://questionsmedicales.fr/mesh/D000074080?mesh_terms=Immunization+Programs&page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Protéines MutS", "description": "Quels sont les symptômes d'une mutation de MutS ?\nLes symptômes sont-ils toujours présents ?\nComment les symptômes varient-ils selon les individus ?\nLes symptômes peuvent-ils apparaître tardivement ?\nY a-t-il des symptômes associés à d'autres maladies ?", "url": "https://questionsmedicales.fr/mesh/D000074080?mesh_terms=Immunization+Programs&page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Protéines MutS", "description": "Comment prévenir les cancers liés à MutS ?\nLes changements de mode de vie aident-ils ?\nLes tests génétiques sont-ils recommandés ?\nY a-t-il des recommandations alimentaires ?\nLes vaccinations peuvent-elles aider ?", "url": "https://questionsmedicales.fr/mesh/D000074080?mesh_terms=Immunization+Programs&page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Protéines MutS", "description": "Quels traitements sont disponibles pour les cancers liés à MutS ?\nLa thérapie génique est-elle une option ?\nComment la surveillance est-elle effectuée ?\nY a-t-il des traitements préventifs ?\nLes traitements ciblés sont-ils efficaces ?", "url": "https://questionsmedicales.fr/mesh/D000074080?mesh_terms=Immunization+Programs&page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Protéines MutS", "description": "Quelles complications peuvent survenir avec MutS ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nY a-t-il des complications psychologiques ?\nLes complications peuvent-elles être prévenues ?", "url": "https://questionsmedicales.fr/mesh/D000074080?mesh_terms=Immunization+Programs&page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Protéines MutS", "description": "Quels sont les principaux facteurs de risque liés à MutS ?\nL'âge est-il un facteur de risque ?\nLe sexe influence-t-il le risque ?\nLes habitudes de vie jouent-elles un rôle ?\nY a-t-il des facteurs environnementaux à considérer ?", "url": "https://questionsmedicales.fr/mesh/D000074080?mesh_terms=Immunization+Programs&page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une déficience en protéines MutS ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des tests génétiques peuvent identifier des mutations dans les gènes codant pour MutS." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'activité des protéines MutS ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de réparation de l'ADN in vitro peuvent mesurer l'activité des protéines MutS." } }, { "@type": "Question", "name": "Les biopsies peuvent-elles aider au diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des biopsies tumorales peuvent révéler des anomalies dans les protéines MutS." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer un problème avec MutS ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes de cancer héréditaire peuvent suggérer une déficience en MutS." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs biologiques associés à MutS ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux anormaux de certains biomarqueurs peuvent indiquer une dysfonction de MutS." } }, { "@type": "Question", "name": "Quels sont les symptômes d'une mutation de MutS ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les mutations peuvent entraîner des cancers, notamment le cancer colorectal héréditaire." } }, { "@type": "Question", "name": "Les symptômes sont-ils toujours présents ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Non, certains individus porteurs de mutations peuvent ne pas présenter de symptômes visibles." } }, { "@type": "Question", "name": "Comment les symptômes varient-ils selon les individus ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent varier en fonction de l'âge et de l'historique familial." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils apparaître tardivement ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains cancers liés à MutS peuvent se développer plus tard dans la vie." } }, { "@type": "Question", "name": "Y a-t-il des symptômes associés à d'autres maladies ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des symptômes similaires peuvent être observés dans d'autres syndromes de cancer héréditaire." } }, { "@type": "Question", "name": "Comment prévenir les cancers liés à MutS ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention inclut des dépistages réguliers et des conseils génétiques pour les familles." } }, { "@type": "Question", "name": "Les changements de mode de vie aident-ils ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sain peut réduire le risque de cancer, même avec des mutations." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils recommandés ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les tests génétiques peuvent aider à identifier les individus à risque élevé." } }, { "@type": "Question", "name": "Y a-t-il des recommandations alimentaires ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation riche en fibres et en antioxydants est conseillée pour la prévention." } }, { "@type": "Question", "name": "Les vaccinations peuvent-elles aider ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Certaines vaccinations, comme contre le HPV, peuvent réduire le risque de cancers associés." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les cancers liés à MutS ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la chirurgie, la chimiothérapie et l'immunothérapie." } }, { "@type": "Question", "name": "La thérapie génique est-elle une option ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie génique est en recherche, mais pas encore une option standard pour MutS." } }, { "@type": "Question", "name": "Comment la surveillance est-elle effectuée ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Une surveillance régulière par des examens endoscopiques est recommandée pour les porteurs." } }, { "@type": "Question", "name": "Y a-t-il des traitements préventifs ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des interventions chirurgicales prophylactiques peuvent être envisagées pour réduire le risque." } }, { "@type": "Question", "name": "Les traitements ciblés sont-ils efficaces ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements ciblés sont en développement et montrent des résultats prometteurs." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec MutS ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent un risque accru de divers cancers et des syndromes associés." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes." } }, { "@type": "Question", "name": "Comment les complications affectent-elles la qualité de vie ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent réduire la qualité de vie en raison des traitements et des symptômes." } }, { "@type": "Question", "name": "Y a-t-il des complications psychologiques ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diagnostic de mutations MutS peut entraîner de l'anxiété et du stress." } }, { "@type": "Question", "name": "Les complications peuvent-elles être prévenues ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Une surveillance régulière et des interventions précoces peuvent aider à prévenir certaines complications." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque liés à MutS ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux de cancer et les mutations génétiques sont des facteurs clés." } }, { "@type": "Question", "name": "L'âge est-il un facteur de risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque de cancer augmente avec l'âge, surtout chez les porteurs de mutations MutS." } }, { "@type": "Question", "name": "Le sexe influence-t-il le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Certaines mutations peuvent avoir un impact différent selon le sexe, affectant le risque de cancer." } }, { "@type": "Question", "name": "Les habitudes de vie jouent-elles un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des habitudes de vie malsaines peuvent augmenter le risque de cancer chez les porteurs." } }, { "@type": "Question", "name": "Y a-t-il des facteurs environnementaux à considérer ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à certains agents cancérigènes peut augmenter le risque chez les porteurs de MutS." } } ] } ] }

Sources (10000 au total)

Impact of the national hepatitis B immunization program in China: a modeling study.

Elimination of hepatitis B virus (HBV) is a striking challenge for countries with high or moderate disease burden. Therefore, using China as a practical case to share experiences for similar countries... We constructed an expanded Susceptible-Exposed-Infectious-Recovered (SEIR) model and decision tree-Markov model to estimate the epidemic of HBV in China, assess the feasibility of 2030 Elimination Goa... Between 1990 and 2020, the number of chronic HBV infections decreased by 33.9%. The current status quo would lead to 55.73 million infections (3.95% prevalence) in 2030, compared to 90.63 million (6.4... Our findings proved the HBV vaccination has demonstrated a substantial positive impact on controlling the epidemic of HBV in terms of effectiveness and economy after about 30 years of implementation o...

Parental knowledge on the respiratory syncytial virus before the nirsevimab immunization program: Attitudes toward immunization in an autonomous community of Spain.

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in young children and associated with most bronchiolitis- and pneumonia-related hospitalizations. A new pre...

Cost-benefit analysis of rotavirus vaccine included in the national immunization program in China.

Globally, rotavirus is a leading cause of severe acute gastroenteritis among children aged under 5 years and has a significant economic cost. Currently, rotavirus vaccines are only included in the pri... A decision tree Markov model was constructed to evaluate the cost-benefit of universal immunization with three doses of rotavirus vaccine for a 2019 birth cohort of Chinese children. Costs of the univ... For the 2019 birth cohort of Chinese infants, inclusion of RotaTeq in NIP was estimated to prevent 5,677,911 cases of rotavirus infection, with net savings of $1.1 billion in total societal costs. A c... Introducing rotavirus vaccine into the China NIP would have significant costs from a societal perspective at the current private market price....

Investigation of non-National Immunization Program vaccination intentions in rural areas of China.

China's current immunization program was revised in 2007. Some common childhood vaccines such as those for influenza, pediatric pneumonia, Haemophilus influenzae, varicella, and rotavirus have not bee... A qualitative method of in-depth interviews were conducted for this study. We interviewed 30 rural parents in a central Chinese village to investigate their awareness of non-NIP vaccines and their vac... This study summarized the individual and social level factors influencing the non-NIP vaccination intention of rural parents. The individual level factors include four themes: perceived severity with ... Based on these influencing factors, this study constructs a structural model for non-NIP vaccination decision-making process in rural areas of China. The results play a guiding role in directing atten...

Vaccination compliance of selected childhood immunization programs and the socio-determinant factors in Nigeria.

Adherence to full vaccination is important in preventing childhood diseases. The aim of this study was to evaluate the level of compliance to full vaccination and identify the socio-cultural factors a... The socioeconomic variables associated with each of the four binary dependent variables of whether or not a child is fully vaccinated against tetanus, BCG, measles, and pentavalent were determined usi... While compliance to full tetanus and BCG vaccinations was > 60% at the national level, less than 50% and 10% full vaccination compliance were recorded for pentavalent and measles vaccinations, respect... The socio-cultural factors associated with achieving full vaccination coverage in Nigeria in this study should drive the implementation of policies that will be best suited to each geopolitical zone o...

Economic assessment of incorporating the hexavalent vaccine as part of the National Immunization Program of Peru.

This study aimed to estimate the economic impact of replacing the current Peruvian primary immunization scheme for infants under 1 year old with an alternative scheme with similar efficacy, based on a... A cost-minimization analysis compared the costs associated with vaccine administration, adverse reactions medical treatment, logistical activities, and indirect social costs associated with time spent... Incorporating the hexavalent vaccine would result in a 15.5% net increase in healthcare budget expenditure ($48,281,706 vs $55,744,653). Vaccination costs would increase by 54.1%, whereas logistical a... Despite of the significant reduction of logistical and adverse reaction costs, including the hexavalent vaccine into the National Immunization Program of Peru in place of the current vaccination schem...

Resilience learning from the COVID-19 pandemic and its relevance for routine immunization programs.

The COVID-19 pandemic represents a threat that has posed a challenge to public health response and threatens immunization programs globally. Despite recommendations to continue routine immunization se... We conducted a systematic literature review to identify studies globally that described how indicators of health system resilience, defined using the Resilient Health System Framework, enabled routine... Our study demonstrates the use of tools that contributed to immunization program resilience during the COVID-19 pandemic in all geographic regions and for countries with different income levels. These...